Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

European shares dip as ex-divs, cyclicals weigh; results boost Aegon, Coca Cola HBC

Published 10/08/2017, 05:30 pm
Updated 10/08/2017, 05:40 pm
© Reuters.  European shares dip as ex-divs, cyclicals weigh; results boost Aegon, Coca Cola HBC
UK100
-
DE40
-
LLOY
-
AEGN
-
ADEN
-
OMVV
-
LXSG
-
RIO
-
AAL
-
BT
-
GLPG
-
STOXX
-
CCH
-
SFRGR
-
STX50EEX
-
SX7P
-
SXPP
-
ATCA
-

LONDON, Aug 10 (Reuters) - European shares slipped in early deals on Thursday, extending losses as shares in cyclical sectors fell and some large firms went ex-dividend, while earnings spurred some large individual company moves.

The pan-European STOXX 600 .STOXX index was down 0.2 percent as basic resources .SXPP and banks .SX7P fell, while euro zone blue chips .STOXX50E also declined 0.2 percent.

Britain's FTSE 100 .FTSE dropped 0.6 percent as heavyweights Anglo American AAL.L , BT Group BT.L , Rio Tinto RIO.L and Lloyds LLOY.L fell after going ex-dividend, while Germany's DAX .GDAXI retreated 0.1 percent.

While rising political tensions between the U.S. and North Korea hit risky assets globally in the previous session, with financials leading losses amongst European equities, results were the dominant focus on Thursday.

Shares in insurer Aegon AEGN.AS and Coca Cola HBC CCH.L rose 8.3 percent and 7.9 percent respectively after their updates.

Shares in staffing firm Adecco ADEN.S , Lanxess LXSG.DE and oil and gas group OMV OMVV.VI were among the biggest fallers, dropping 3.6 percent to 4.8 percent following their second-quarter earnings.

Around 70 percent of MSCI Europe firms have reported second quarter earnings so far, of which more than 60 percent have either met or beaten analysts' expectations, according to Thomson Reuters data.

Financials and the energy and materials sectors have seen the biggest beats, while industrials have had the biggest misses.

Shares in Belgian biotech firm Galapagos GLPG.AS were the top risers on the STOXX, surging more than 15 percent after a successful mid-stage study for its lung fibrosis drug. company SFR SFRGR.PA was up 9.7 percent after Altice ATCA.AS raised its stake in the firm to more than 95 percent and said that it was planning a full buyout offer for remaining shares.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.